Introducing DataLookout: Stop Manually Checking ClinicalTrials.gov

You already know the problem

You open ClinicalTrials.gov. You search for your disease area. You scroll through results and try to spot what's different from last week. Did that Phase 3 start recruiting? Did Pfizer update their endpoint? Is there a new sponsor in your space?

You can't tell at a glance. ClinicalTrials.gov keeps the full history of every trial, and its RSS feeds can tell you that a record in your search was updated. What the registry does not do is say what changed inside the record, or roll those changes up across a disease area.

The real risk isn't wasted time. It's the changes you never see. A competitor opens recruitment in your indication. A Phase 3 trial quietly modifies its primary endpoint. A new sponsor files their first trial in your disease area. By the time you find out at a conference six months later, you've already lost the first-mover advantage.

Enterprise monitoring platforms solve this, but they don't publish pricing — access starts with a demo request and a sales conversation. Most biotech teams just live with the manual process. Or they skip it entirely.

What DataLookout does

We check ClinicalTrials.gov every day. When something changes on a trial you care about, we tell you. That's the whole product.

155,011

Trials Monitored

65,197

Recruiting

Disease Areas

Daily

Updates

Counts as of August 23, 2026. At launch in March 2026 the monitored set was 46,689 trials; coverage was expanded to all active-status trials in July 2026.

We detect four types of changes

Status changes like recruitment opening, trials completing, or studies getting suspended
Protocol amendments including primary endpoint modifications and enrollment target updates
Site expansions when new locations get added or enrollment scales up
New sponsor entrants when a company files its first trial in a disease area

Every change gets a severity label. A termination, a suspension, or a primary endpoint change is critical. A trial opening recruitment is notable. A site count going from 18 to 23 is minor. You decide what matters to you.

How it works

Build a watchlist

Pick the sponsors and diseases you care about. Track Pfizer in NSCLC, AstraZeneca in breast cancer, or any combination you want.

Get email digests

When something changes, you get an email. Pick daily or weekly. Only sends when there's actual news.

Landscape reports

See every sponsor in a disease area, grouped by trial phase. Spot who's expanding, who's stalling, who just showed up.

Pipeline Pulse

86 disease areas ranked by how much trial activity is happening right now. Find out where pharma is concentrating.

Who uses this

Biotech BD managers who need to know what competitors are doing in the clinic
Clinical ops teams tracking status changes across their own portfolio
Pharma analysts who need competitive intelligence without an enterprise procurement cycle
Investors and consultants following therapeutic area trends

What it costs

The free plan is free forever. You get one sponsor and one disease on your watchlist, daily change detection, and full access to search 150,000+ trials. No credit card. No expiry.

If you need more watchlists and full landscape reports, Starter is $49/month. Pro is $149/month with unlimited watchlists and CSV export.

For comparison: Enterprise clinical trial intelligence platforms like Citeline Trialtrove and GlobalData don't publish pricing; access starts with a demo request and a sales conversation.

Try it now

Sign up takes 30 seconds. Pick a sponsor and a disease and you'll have your first watchlist running before your coffee gets cold.

Get Started Free

Updated July 21, 2026: an earlier version claimed ClinicalTrials.gov offered no way to see how a trial record had changed. It does, one record at a time, via each study's Record History tab. The sentence was corrected. More on our Trials at Risk post.

The Obesity Pipeline Has 951 Trials and One Clear Leader